
1. Malar J. 2015 Dec 8;14:493. doi: 10.1186/s12936-015-1008-5.

Beninese children with cerebral malaria do not develop humoral immunity against
the IT4-VAR19-DC8 PfEMP1 variant linked to EPCR and brain endothelial binding.

Nunes-Silva S(1)(2)(3)(4), Dechavanne S(5)(6)(7)(8), Moussiliou A(9)(10)(11),
Pstrąg N(12)(13)(14)(15), Semblat JP(16)(17)(18)(19), Gangnard S(20)(21)(22)(23),
Tuikue-Ndam N(24)(25)(26), Deloron P(27)(28)(29), Chêne A(30)(31)(32)(33), Gamain
B(34)(35)(36)(37).

Author information: 
(1)Inserm UMR_1134, Paris, France. ana-sofia.nunes-da-silva@inserm.fr.
(2)Université Paris Diderot, Sorbonne Paris Cité, UMR_S1134, Paris, France.
ana-sofia.nunes-da-silva@inserm.fr.
(3)Institut National de la Transfusion Sanguine, 6 rue Alexandre Cabanel, 75015, 
Paris, France. ana-sofia.nunes-da-silva@inserm.fr.
(4)Laboratory of Excellence GR-Ex, Paris, France.
ana-sofia.nunes-da-silva@inserm.fr.
(5)Inserm UMR_1134, Paris, France. sebdechavanne@gmail.com.
(6)Université Paris Diderot, Sorbonne Paris Cité, UMR_S1134, Paris, France.
sebdechavanne@gmail.com.
(7)Institut National de la Transfusion Sanguine, 6 rue Alexandre Cabanel, 75015, 
Paris, France. sebdechavanne@gmail.com.
(8)Laboratory of Excellence GR-Ex, Paris, France. sebdechavanne@gmail.com.
(9)Laboratory of Excellence GR-Ex, Paris, France. azizathmoussiliou@yahoo.fr.
(10)Institut de Recherche pour le développement, UMR_216, Mère et enfant face aux
infections tropicales, Paris, France. azizathmoussiliou@yahoo.fr.
(11)Faculté de pharmacie, PRES Sorbonne Paris Cité, Paris, France.
azizathmoussiliou@yahoo.fr.
(12)Inserm UMR_1134, Paris, France. natalia.pstrag@gmail.com.
(13)Université Paris Diderot, Sorbonne Paris Cité, UMR_S1134, Paris, France.
natalia.pstrag@gmail.com.
(14)Institut National de la Transfusion Sanguine, 6 rue Alexandre Cabanel, 75015,
Paris, France. natalia.pstrag@gmail.com.
(15)Laboratory of Excellence GR-Ex, Paris, France. natalia.pstrag@gmail.com.
(16)Inserm UMR_1134, Paris, France. jean-philippe.semblat@inserm.fr.
(17)Université Paris Diderot, Sorbonne Paris Cité, UMR_S1134, Paris, France.
jean-philippe.semblat@inserm.fr.
(18)Institut National de la Transfusion Sanguine, 6 rue Alexandre Cabanel, 75015,
Paris, France. jean-philippe.semblat@inserm.fr.
(19)Laboratory of Excellence GR-Ex, Paris, France.
jean-philippe.semblat@inserm.fr.
(20)Inserm UMR_1134, Paris, France. stephane.gangnard@pasteur.fr.
(21)Université Paris Diderot, Sorbonne Paris Cité, UMR_S1134, Paris, France.
stephane.gangnard@pasteur.fr.
(22)Institut National de la Transfusion Sanguine, 6 rue Alexandre Cabanel, 75015,
Paris, France. stephane.gangnard@pasteur.fr.
(23)Laboratory of Excellence GR-Ex, Paris, France. stephane.gangnard@pasteur.fr.
(24)Laboratory of Excellence GR-Ex, Paris, France. nicaise.ndam@ird.fr.
(25)Institut de Recherche pour le développement, UMR_216, Mère et enfant face aux
infections tropicales, Paris, France. nicaise.ndam@ird.fr.
(26)Faculté de pharmacie, PRES Sorbonne Paris Cité, Paris, France.
nicaise.ndam@ird.fr.
(27)Laboratory of Excellence GR-Ex, Paris, France. philippe.deloron@ird.fr.
(28)Institut de Recherche pour le développement, UMR_216, Mère et enfant face aux
infections tropicales, Paris, France. philippe.deloron@ird.fr.
(29)Faculté de pharmacie, PRES Sorbonne Paris Cité, Paris, France.
philippe.deloron@ird.fr.
(30)Inserm UMR_1134, Paris, France. arnaud.chene@inserm.fr.
(31)Université Paris Diderot, Sorbonne Paris Cité, UMR_S1134, Paris, France.
arnaud.chene@inserm.fr.
(32)Institut National de la Transfusion Sanguine, 6 rue Alexandre Cabanel, 75015,
Paris, France. arnaud.chene@inserm.fr.
(33)Laboratory of Excellence GR-Ex, Paris, France. arnaud.chene@inserm.fr.
(34)Inserm UMR_1134, Paris, France. benoit.gamain@inserm.fr.
(35)Université Paris Diderot, Sorbonne Paris Cité, UMR_S1134, Paris, France.
benoit.gamain@inserm.fr.
(36)Institut National de la Transfusion Sanguine, 6 rue Alexandre Cabanel, 75015,
Paris, France. benoit.gamain@inserm.fr.
(37)Laboratory of Excellence GR-Ex, Paris, France. benoit.gamain@inserm.fr.

Erratum in
    Malar J. 2016;15:22.

BACKGROUND: Malaria is still one of the most prevalent infectious diseases in the
world. Sequestration of infected erythrocytes (IEs) is the prime mediator of
disease. Cytoadhesion of IEs is mediated by members of the highly diverse
Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1). A restricted
sub-set of var genes encoding for PfEMP1s possessing the domain cassettes DC8 and
DC13 were found to bind to the endothelial protein C receptor (EPCR). These var
genes were shown to be highly expressed by parasites from patients with severe
malaria clinical outcomes compared to those from patients with uncomplicated
symptoms.
METHODS: In order to further study the molecular mechanisms underlying DC8/DC13
expressing IEs adhesion to EPCR, a method was developed to produce highly pure
recombinant EPCR. The IT4 parasite strain was selected on either anti-IT4-VAR19
purified IgG, EPCR or human brain endothelial cell line and their var gene
expression profiles as well as their binding phenotypes were compared. The
N-terminal region of IT4-VAR19 comprising a full-length DC8 cassette as well as
the single EPCR binding CIDRα1.1 domain were also produced, and their immune
recognition (IgG) was assessed using plasma samples from Beninese children
presenting acute mild malaria, severe malaria or cerebral malaria at the time of 
their admission to the clinic, and from convalescent-phase plasma collected 30
days after anti-malarial treatment.
RESULTS: The multi-domain VAR19-NTS-DBLγ6 binds to EPCR with a greater affinity
than the CIDRα1.1 domain alone and this study also demonstrates that
VAR19-NTS-DBLγ6 binding to the EPCR-expressing endothelial cell line (HBEC5i) is 
more pronounced than that of the CIDRα1.1 domain alone. IT4-VAR19 represents the 
preferentially expressed-PfEMP1 when FCR3-IEs are selected based on their
capability to bind EPCR. Notably, no significant difference in the levels of
antibodies towards IT4-VAR19 antigens was observed within all clinical groups
between plasma samples collected during the acute malaria phase compared to
samples collected 30 days after anti-malaria treatment.
CONCLUSIONS: These data indicate that even being the preferentially selected
IT4-EPCR-binding variant, the IT4-VAR19-DC8 region does not appear to be
associated with the acquisition of antibodies during a single severe paediatric
malaria episode in Benin.

DOI: 10.1186/s12936-015-1008-5 
PMCID: PMC4672576
PMID: 26646943  [Indexed for MEDLINE]

